Susavion has a robust pipeline of preclinical drug candidates for immunotherapy.
Multiple therapeutic indications
Susavion has developed a series of peptides that are effective at sub-nanomolar concentrations. These drugs are showing early promise in enhancing the immune defense in treatment of cancer and viral infections.
svL4 has been shown to significantly extend life of mice with ovarian cancer and significantly extends life when administered in conjunction with low doses of radiation in a glioblastoma brain tumor mouse model. svL4 reduces growth of melanoma tumors and dramatically lowers the bad, regulatory T cells within tumors.
Other peptides were shown to be effective in eliminating HIV-1 in cultures of peripheral blood mononuclear cells in the presence of non-neutralizing antibodies from HIV-positive patients.
|Drug Candidate||Receptor||Therapeutic Area, Indication||Status|
|svL4||C-Type Lectins||Oncology||in vivo studies|
|sv6B||C-, I-Type Lectins||Oncology, Anti-viral||in vivo studies|
|svH1C||I-Type Lectins||Anti-viral||in vivo studies|
|svH1D||I-Type Lectins||Anti-viral||In vitro assays Cell culture|
|svC2||Anti-viral||in vitro studies|
|sv6D||C-Type Lectins||Oncology||in vivo studies|